Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131989 | 0.83 | — | — | |
| SCHEMBL16367524 | 0.83 | TSHR (0.35) | LMNATDP1KDM4ECYP2D6SPHK1 | |
| SCHEMBL18398906 | 0.80 | LMNA (0.59) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL18398907 | 0.80 | LMNA (0.59) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL9669465 | 0.80 | LMNA (0.59) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL7419723 | 0.80 | TSHR (0.41) | LMNATDP1KDM4ECYP2D6SPHK1 | |
| SCHEMBL14543846 | 0.79 | LMNA (0.45) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL4133282 | 0.79 | LMNA (0.45) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL12009794 | 0.79 | LMNA (0.45) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL14753821 | 0.79 | LMNA (0.45) | LMNAL3MBTL1TDP1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060110352-A1 | Cosmetic, pharmaceutical and dermatological compositions | CLARIANT GMBH | 2006-05-25 | — | — | US | disclosed |
| US-6248338-B1 | CROSSLINKED STARCH | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION | 2001-06-19 | — | — | US | disclosed |
| US-5864032-A | Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides | AMERSHAM INTERNATIONAL PLC (GB) | 1999-01-26 | — | — | US | disclosed |
| US-5567811-A | Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides | AMERSHAM INTERNATIONAL PLC (GB) | 1996-10-22 | — | — | US | disclosed |
| EP-0527184-B1 | PHOSPHORAMIDITE DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF IN THE INCORPORATION OF REPORTER GROUPS ON SYNTHETIC OLIGONUCLEOTIDES | AMERSHAM INT PLC (GB) | 1995-08-02 | — | — | EP | disclosed |
| EP-0527184-A1 | PHOSPHORAMIDITE DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF IN THE INCORPORATION OF REPORTER GROUPS ON SYNTHETIC OLIGONUCLEOTIDES. | AMERSHAM INT PLC (GB) | 1993-02-17 | — | — | EP | disclosed |
| WO-1991017169-A1 | PHOSPHORAMIDITE DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF IN THE INCORPORATION OF REPORTER GROUPS ON SYNTHETIC OLIGONUCLEOTIDES | AMERSHAM INTERNATIONAL PLC (GB) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060110352-A1 | Cosmetic, pharmaceutical and dermatological compositions | CACNA1C, CACNA1G, CACNA1E | LMNA 979/4885L3MBTL1 2927/4885TDP1 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.